Logotheti Marianthi, Agioutantis Panagiotis, Katsaounou Paraskevi, Loutrari Heleni
G.P. Livanos and M. Simou Laboratories, 1st Department of Critical Care Medicine & Pulmonary Services, Evangelismos Hospital, Medical School, National Kapodistrian University of Athens, 3 Ploutarchou Str., 10675 Athens, Greece.
Biotechnology Laboratory, School of Chemical Engineering, National Technical University of Athens, 5 Iroon Polytechniou Str., Zografou Campus, 15780 Athens, Greece.
J Pers Med. 2021 Dec 5;11(12):1299. doi: 10.3390/jpm11121299.
Asthma is a multifactorial inflammatory disorder of the respiratory system characterized by high diversity in clinical manifestations, underlying pathological mechanisms and response to treatment. It is generally established that human microbiota plays an essential role in shaping a healthy immune response, while its perturbation can cause chronic inflammation related to a wide range of diseases, including asthma. Systems biology approaches encompassing microbiome analysis can offer valuable platforms towards a global understanding of asthma complexity and improving patients' classification, status monitoring and therapeutic choices. In the present review, we summarize recent studies exploring the contribution of microbiota dysbiosis to asthma pathogenesis and heterogeneity in the context of asthma phenotypes-endotypes and administered medication. We subsequently focus on emerging efforts to gain deeper insights into microbiota-host interactions driving asthma complexity by integrating microbiome and host multi-omics data. One of the most prominent achievements of these research efforts is the association of refractory neutrophilic asthma with certain microbial signatures, including predominant pathogenic bacterial taxa (such as phyla, class, especially species from and genera). Overall, despite existing challenges, large-scale multi-omics endeavors may provide promising biomarkers and therapeutic targets for future development of novel microbe-based personalized strategies for diagnosis, prevention and/or treatment of uncontrollable asthma.
哮喘是一种呼吸系统的多因素炎症性疾病,其临床表现、潜在病理机制和对治疗的反应具有高度多样性。一般认为,人类微生物群在塑造健康的免疫反应中起着至关重要的作用,而其紊乱会导致与包括哮喘在内的多种疾病相关的慢性炎症。涵盖微生物组分析的系统生物学方法可以为全面理解哮喘的复杂性以及改善患者分类、状态监测和治疗选择提供有价值的平台。在本综述中,我们总结了最近的研究,这些研究在哮喘表型-内型和所用药物的背景下,探讨了微生物群失调对哮喘发病机制和异质性的影响。随后,我们将重点关注通过整合微生物组和宿主多组学数据来更深入了解驱动哮喘复杂性的微生物群-宿主相互作用的新努力。这些研究工作最显著的成果之一是难治性嗜中性粒细胞哮喘与某些微生物特征的关联,包括主要的致病细菌分类群(如门、纲,特别是来自 和 属的物种)。总体而言,尽管存在挑战,但大规模多组学研究可能为未来开发基于微生物的新型个性化策略用于诊断、预防和/或治疗难治性哮喘提供有前景的生物标志物和治疗靶点。